AACR's annual cancer progress report highlights promising advances for patients

The American Association for Cancer Research (AACR) published its 16th annual Cancer Progress Report, showcasing promising advances in cancer research, prevention, detection, and treatment. This comprehensive report, supported by federal investments in the National Institutes of Health, National Cancer Institute, FDA, and CDC, highlights the latest breakthroughs in understanding, preventing, detecting, and treating cancer.

Key advances mentioned in the report include the potential of weight loss interventions, such as GLP-1 receptor agonists, in reducing the risk of obesity-related cancers. However, evidence regarding their effectiveness remains inconsistent. Artificial intelligence (AI) is revolutionizing cancer research and clinical care, enabling faster and more efficient approaches.

Cancer vaccines are also gaining momentum in the clinic, with new technologies improving vaccine design, identifying new tumor-specific targets, and optimizing combinations with other therapies.

Despite these advancements, cancer continues to affect millions of Americans. In 2026, over 2.1 million new cancer cases are projected to be diagnosed, with more than 626,000 deaths in the United States alone. By 2050, the number of new cancer cases in the U.S. is expected to exceed 2.5 million, representing a 19% increase from current projections.

Additionally, the incidence of early-onset cancers, defined as those diagnosed in people aged 18 to 49, has surged globally, with a nearly 80% increase between 1990 and 2019. Certain gastrointestinal cancers, such as colorectal, stomach, and esophageal cancers, have contributed significantly to this rise. The AACR emphasizes the need for continued investment in medical research, collaboration across disciplines, and support for the next generation of cancer scientists to accelerate discoveries and translate them into precise, biology-driven approaches that will transform cancer patients' lives.